Skip to content

Emma Höglund has been appointed as the new CEO of Neobiomics

Emma Höglund has been appointed as the new Chief Executive Officer (CEO) of Neobiomics, starting her position on April 15, 2024. Stefan Johansson, co-founder and current CEO, will take on a new position as Chief Medical Officer (CMO).

Emma Höglund brings more than 15 years of experience from the healthcare industry including international commercial roles in the life sciences (MSD/Merck & Co and Novartis) and most recently from the Real-World-Data industry (BCB Medical). Her track record involves driving growth, strategic business development and global product launches while developing strong teams to achieve results. Emma holds an M.Sc. in Economics & Business from the Stockholm School of Economics.

With this recruitment, Stefan Johansson will be focusing on the R&D aspects of current
and future products. Like before, he will keep working part-time as a consultant
neonatologist in Stockholm.

Stefan Johansson comments: “I am so glad Emma Höglund is joining Neobiomics. Her
extensive experience in leading change will enable us to take new and important steps
in developing Neobiomics and making an even bigger impact.

I am truly excited to take on this new role and together with the team lead Neobiomics into its next phase. My professional purpose lies in making healthcare products and services contribute to better health. Neobiomics is uniquely positioned to provide innovative
products, improving care for newborns and their families
”, says Emma Höglund.

For queries or additional information, kindly feel free to contact us at